close

Fenwick & West Represents Loxo Oncology in Initial Public Offering

July 31, 2014

Fenwick & West represented Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, in its initial public offering. The company sold 5,261,538 shares of its common stock at a price to the public of $13.00 per share. Concurrent with the offering, Fenwick assisted Loxo in selling through a private placement 230,769 shares of its common stock to New Enterprise Associates 14, L.P., an existing stockholder, at the initial public offering price.

Cowen and Company, LLC and Stifel acted as joint book-running managers for the offering. JMP Securities LLC and Oppenheimer & Co. Inc. acted as co-managers.

The Fenwick transaction team included corporate attorneys Robert Freedman, Matthew Rossiter, Effie Toshav, Jane Shen, Julia Forbess and Tahir Golden and executive compensation and employee benefits attorney Adriana Sherwood.